|
|
|
September 10, 2009
QuatRx Pharmaceuticals Reports Positive Ophena Pivotal Phase III Results
KVP financed QuatRx and a team led by Bob Zerbe to acquire and develop Ophena for the treatment of postmenopausal vulvovaginal atrophy in 2004. The company recently announced positive efficacy results from the second of two patient cohorts in the second pivotal Phase 3 study. This study, together with the recent completion of a long-term safety study marks the end of the company’s comprehensive Phase 3 efficacy and safety program and positions QuatRx to file a New Drug Application with the U.S. Food and Drug Administration in early 2010. Read more here. Read more here.
--------------------------------
Back to News
|
|
| |
